Carfilzomib and bortezomib were obtained from LC laboratories, ONX-0914 was obtained from MedChemExpress. LU-102, LU-015i, and activity-based probes were kindly provided by Drs. Bogdan Florea and Herman Overkleeft (Univ of Leiden, the Netherlands). Suc-LLVY-amc was obtained from Bachem. All other substrates were custom synthesized by China Peptide.
Onx 0914
Manufactured by MedChemExpress
Sourced in United States
ONX-0914 is a selective inhibitor of the proteasome subunit X (also known as LMP7 or PSMB5). It is a laboratory research tool used for studying the role of the proteasome in various biological processes.
Automatically generated - may contain errors
Lab products found in correlation
Bortezomib, by LC Laboratories (1 mentions)
Carfilzomib, by LC Laboratories (1 mentions)
Suc llvy amc, by Bachem (1 mentions)
Dimethyl sulfoxide (dmso), by Absin (1 mentions)
Ly294002, by MedChemExpress (1 mentions)
Ionomycin calcium salt, by Merck Group (1 mentions)
Marizomib, by MedChemExpress (1 mentions)
Birb796, by MedChemExpress (1 mentions)
Valinomycin, by Cayman Chemical (1 mentions)
4 6 diamidino 2 phenylindole dapi 14285, by Cayman Chemical (1 mentions)
Sb203580, by MedChemExpress (1 mentions)
3 protocols using onx 0914
1
Proteasome Inhibitor Characterization
2
Neuroprotective Effects of ONX-0914 and LY294002 in Hypoxic-Ischemic Brain Damage
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Rats that died or those in which the model was not successfully established were excluded, the remaining rats were randomly divided into the following groups: Sham operation (Sham, N = 60), model (HIBD, N = 108), dimethyl sulfoxide (DMSO) treatment (intraperitoneally injected with 15 µL DMSO solvent, N = 30), 10 mg/kg ONX-0914 treatment (intraperitoneally injected with 15 µL ONX-0914 at a dose of 10 mg/kg, N = 6), 20 mg/kg ONX-0914 treatment (intraperitoneally injected with 15 µL ONX-0914 at a dose of 20 mg/kg, N = 30), 30 mg/kg ONX-0914 treatment (intraperitoneally injected with 15 µL ONX-0914 at a dose of 30 mg/kg, N = 6), LY294002 treatment (intraperitoneally injected with 15 µL 0.3 mg/kg of LY294002, N = 6), and ONX-0914 + LY294002 treatment (intraperitoneally injected with 15 µL 20 mg/kg ONX-0914 and 15 µL 0.3 mg/kg of LY294002, N = 6). ONX-0914 (MedChemExpress Co., Ltd.) and LY294002 (MedChemExpress Co., Ltd.) were dissolved in DMSO (Absin Bioscience Inc.) to the same volume, and the timing of injection is 2 h after the model was established.
3
Cell Signaling Pathway Modulation
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Venetoclax (Cat. N° HY-15531), BIRB796 (doramapimod; HY-10320), SB203580 (HY-10256), M3258 (HY-111790), ML604440 (HY-114170), marizomib (HY-10985), dithiothreitol (HY-15917; DTT), ONX-0914 (HY-13207), quinoline-Val-Asp-difluorophenoxymethylketone (QVD-OPh; HY-12305), and adenosine 5’-triphosphate (HY-B2176; ATP) were from MedChemExpress (Monmouth Junction, NJ, USA). 4′,6-Diamidino-2-phenylindole (DAPI; 14285) and valinomycin were from Cayman Chemical (Ann Arbor, MI, USA). IFNγ (Cat. N° IF002), phorbol 12-myristate 13-acetate (PMA; P8139), and ionomycin calcium salt (I0634s) were from Sigma-Aldrich (St. Louis, MO, USA). Recombinant human sCD40 ligand (sCD40L; 310-02) was from PeproTech (London, UK).
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!